ClinicalTrials.gg
CompletedNCT01297569OPTIMALUpdated Feb 23, 2017

Ranibizumab "Treat and Extend" in Diabetic Macular Edma

A Phase 4 interventional study of Ranibizumab in Diabetic Macular Edema, sponsored by Novartis Pharmaceuticals. Completed at 1 site in Norway. Open to participants aged 18 Years to 18 Years. Per ClinicalTrials.gov, last updated 2017-02-23.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 91 studies testing ranibizumab in Macular Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Macular Edema.

Enrollment
77th of 91
7 · median 50
Started
2011
with 10 others
Phase 4
26 of 91
none open now
Registered
28th of 91
by date
Lead sponsor
21 of 91
Novartis Pharmaceuticals

Among the 91 studies testing ranibizumab in Macular Edema, this one is the 77th largest by enrollment, is one of 11 that started in 2011, is one of 26 in phase 4, and was the 28th registered.

Macular Edema

758 studies on the registry are indexed under Macular Edema; 65 are open to participants now.

Browse Macular Edema studies →

Open to participants now

None of the 91 studies testing ranibizumab in Macular Edema is open now. The open studies under Macular Edema, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 43 Macular Edema studies recruiting now, 31 (72%) set no upper age limit and 7 (16%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 91 studies testing ranibizumab in Macular Edema as a file.
02

Study summary

This study is designed to explore a more individualized treatment regime based on achievement of disease stability to define a personal optimal treatment interval with ranibizumab in patients with visual impairment due to diabetic macular edema.

03

Conditions studied

  • Diabetic Macular Edema

Keywords

  • Diabetic macular edema
  • Macular edema
  • DME
  • Diabetic retinopathy
  • Diabetic eye disease
  • anti-VEGF
  • ranibizumab
  • Lucentis
04

Who can participate

Ages eligible
18 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Visual impairment due to focal or diffuse macular edema with center involvement
  • Diabetes type 1 or 2, \< 12.0%
  • CRT = or > 250 μm

Exclusion criteria

Exclusion Criteria:

  • Active inflammation or infection
  • Uncontrolled glaucoma
  • Iris neovascularization, active proliferative retinopathy or vitreomacular traction
  • Prior laser photocoagulation according to defined timelines
  • History of stroke, uncontrolled hypertension

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Ranibizumab

    Drug: Ranibizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Best Corrected Visual Acuity(BCVA)

    Time frame: from month 0 (baseline) to month 12

Secondary outcomes

  1. change in central retinal thickness (CRT)

    Time frame: from month 0 to month 12

  2. the number of injections needed

    Time frame: 12 months

  3. the number of patients with improvement in BCVA from baseline

    Time frame: 12 months

  4. the number of patients with > 5, 10 and 15 letters improvement from baseline, the latter including patients reaching BCVA >84

    Time frame: 12 months

07

Study locations

1 site
  • Novartis Investigative Site
    Oslo, 0264, Norway
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2011, a primary completion of Nov 2012 and a completion of Nov 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2011
First posted
Feb 16, 2011
Start
Jan 2011
Primary completionActual
Nov 2012
CompletionActual
Nov 2012
Last update
Feb 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01297569
Responsible party
Sponsor
First posted
Feb 16, 2011
Start date
Jan 2011
Primary completion
Nov 2012
Completion
Nov 2012
Last update
Feb 23, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ranibizumab

Start the discussion